| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shenzhen Weiguang Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.03 |
| 52 Week High | CN¥42.18 |
| 52 Week Low | CN¥22.05 |
| Beta | 0.12 |
| 1 Month Change | 4.05% |
| 3 Month Change | 22.62% |
| 1 Year Change | -5.51% |
| 3 Year Change | -6.18% |
| 5 Year Change | n/a |
| Change since IPO | -28.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2880 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 4.0% | 4.3% | 2.9% |
| 1Y | -5.5% | -21.4% | -13.2% |
Return vs Industry: 002880 exceeded the CN Biotechs industry which returned -21.4% over the past year.
Return vs Market: 002880 exceeded the CN Market which returned -13.2% over the past year.
Price Volatility
| 2880 volatility | |
|---|---|
| 2880 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002880 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002880's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 796 | Caiping Guo | www.szwg.com |
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous human immunoglobulin (pH4), rabies immunoglobulin, human fibrinogen, coagulation factor, trace proteins, as well as a total of 9 varieties and 21 specifications.
Shenzhen Weiguang Biological Products Co., Ltd. Fundamentals Summary
| 2880 fundamental statistics | |
|---|---|
| Market cap | CN¥6.81b |
| Earnings (TTM) | CN¥195.91m |
| Revenue (TTM) | CN¥991.93m |
34.8x
P/E Ratio6.9x
P/S RatioIs 2880 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2880 income statement (TTM) | |
|---|---|
| Revenue | CN¥991.93m |
| Cost of Revenue | CN¥603.43m |
| Gross Profit | CN¥388.50m |
| Other Expenses | CN¥192.59m |
| Earnings | CN¥195.91m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 39.17% |
| Net Profit Margin | 19.75% |
| Debt/Equity Ratio | 22.9% |
How did 2880 perform over the long term?
See historical performance and comparison